# Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma

> **NCT00415454** · PHASE1 · TERMINATED · sponsor: **Henry Ford Health System** · enrollment: 8 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **GENETIC:** Ad5-yCD/mutTKSR39rep-ADP

## Key facts

- **NCT ID:** NCT00415454
- **Lead sponsor:** Henry Ford Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-11
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Poor enrollment
- **Last updated:** 2011-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00415454

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00415454, "Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of Non-Metastatic Pancreatic Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00415454. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*